SLA is therefore particularly useful for evaluating CFTR function in milder disease phenotypes, such as CFSPID/CRMS, CFTR-RD, and other inconclusive diagnosis. This evidence concerns the gene CFTR and CFTR-related metabolic syndrome/CF screen positive, inconclusive diagnosis.